GSK to buy US biotech firm IDRx for up to $1.15 billion-February 2024-www.financetom.com

GSK to buy US biotech firm IDRx for up to $1.15 billion

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

GSK to buy US biotech firm IDRx for up to $1.15 billion

Jan 12, 2025 11:18 PM

Jan 13 (Reuters) - British drugmaker GSK said on

Monday that it would pay up to $1.15 billion to buy Boston-based

biopharmaceutical firm IDRx, which is developing a treatment for

a rare type of tumour.

Previous page： --Pathward Financial Keeps Quarterly Cash Dividend at $0.05 a Share; Payable Oct. 1 to Holders of Record as of Sept. 10 Next page： Accenture Invests in Clika

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Pathward Financial Keeps Quarterly Cash Dividend at $0.05 a Share; Payable Oct. 1 to Holders of Record as of Sept. 10

Aug 21, 2025

09:37 AM EDT, 08/21/2025 (MT Newswires) -- Price: 75.48, Change: -0.27, Percent Change: -0.36 ...

Accenture Invests in Clika

Aug 21, 2025

09:38 AM EDT, 08/21/2025 (MT Newswires) -- Accenture ( ACN ) said Thursday that it has invested in high-performance AI compression platform company Clika to expand its intelligent edge and infrastructure engineering capabilities. No financial terms were disclosed but the company said the investment was made through Accenture Ventures. Price: 252.72, Change: -2.34, Percent Change: -0.92 ...

--Raymond James Financial Keeps Quarterly Dividend at $0.50 a Share; Payable Oct. 15 to Holders of Record as of Oct. 1

Aug 21, 2025

09:38 AM EDT, 08/21/2025 (MT Newswires) -- Price: 162.76, Change: +0.27, Percent Change: +0.17 ...

Hovnanian Enterprises Fiscal Q3 Earnings Fall, Revenue Rises; Shares Decline

Aug 21, 2025

09:37 AM EDT, 08/21/2025 (MT Newswires) -- Hovnanian Enterprises ( HOV ) shares were down over 4% in early trading Thursday after the company reported fiscal Q3 earnings of $1.99 per diluted share, down from $9.75 a year earlier. Total revenue for the quarter ended July 31 was $800.6 million, up from $722.7 million a year earlier. An analyst surveyed...